Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Hemangiosarcoma 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Melanoma 1Gliosarcoma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 18Ifosfamide 13Radiotherapy 8Paclitaxel 7pazopanib 6pembrolizumab 4Gemcitabine 4Filgrastim 4Chemotherapy, Adjuvant 4Bevacizumab 4spartalizumab 3durvalumab 3Sorafenib 3Propranolol 3Nivolumab 3Ipilimumab 3Imatinib Mesylate 3Etoposide 3Epirubicin 3Docetaxel 3Carboplatin 3trebananib 2regorafenib 2cixutumumab 2cemiplimab 2carotuximab 2brostallicin 2belinostat 2balstilimab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hemangiosarcoma × balstilimab × Sarcoma × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡